All In Biotech

Drug Trial Radar · NCT07341373

A Single Bolus, 12-hour Euglycemic Clamp Study of the Safety, Pharmacokinetics (PK) and Glucodynamics (GD) of Intraperitoneal (IP) Portal Insulin U-500

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

29

Actual

Start

Feb 10, 2026

Primary completion

Sep 30, 2026

Study completion Sep 30, 2026

Sponsor

Lead sponsor
Portal Diabetes, Inc.Industry
Sponsor type
Industry
First posted
Jan 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to assess the safety of a new U500 insulin formulation and to determine how rapidly it is absorbed and how long it takes to act when administered intraperitoneally. The trial will be conducted in people with Type 1 Diabetes. The main questions it aims to answer are: Is the drug safe and tolerable when administered intraperitoneally? How fast is it absorbed, and how long does it take to act? Researchers will compare the investigational product (PI-U500) with Humulin R U500 administered intraperitoneally and Lyumjev U100 administered subcutaneously. Participants will undergo a 12-hour clamp procedure in which their blood glucose will be maintained stable via glucose infusion at variable rates after a single intraperitoneal injection of the insulin formulation.

Conditions

  • Type 1 Diabetes

Interventions

  • Portal Insulin U-500Drug

    Intraperitoneal delivery of a single dose at 0.1 U/kg during an euglycemic clamp

  • Portal Insulin U-500Drug

    Intraperitoneal delivery of a single dose at 0.2 U/kg during an euglycemic clamp

  • Portal Insulin U-500Drug

    Intraperitoneal delivery of a single dose at 0.3 U/kg during an euglycemic clamp

  • Humulin R U-500Drug

    Intraperitoneal delivery of a single dose at 0.2 U/kg during an euglycemic clamp

  • Lyumjev U-100 InsulinDrug

    Subcutaneous delivery of a single dose at 0.2 U/kg during an euglycemic clamp

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety: Incidence of adverse eventsTime frame: From enrollment until the follow-up visit, an average of 2 months
  2. Safety: Change from baseline in systolic and diastolic blood pressureTime frame: Will be measured at 2 times, first within 4 hours before drug administration (Pre-clamp) and then after 12 hours of drug administration (post-clamp)
  3. Safety: Change from baseline in temperatureTime frame: Will be measured at 2 times, first within 4 hours before drug administration (Pre-clamp) and then after 12 hours of drug administration (post-clamp)
  4. Safety: Change from baseline in respiratory rateTime frame: Will be measured at 2 times, first within 4 hours before drug administration (Pre-clamp) and then after 12 hours of drug administration (post-clamp)
  5. Safety: Change from baseline in heart rateTime frame: Will be measured at 2 times, first within 4 hours before drug administration (Pre-clamp) and then after 12 hours of drug administration (post-clamp)
  6. Safety: Change from baseline in 12-lead electrocardiogram (ECG) parametersTime frame: Pre-dose and after the end of PK-sampling (720 minutes post-dose)
  7. Safety: Incidence and severity of clinical findings on physical examinationTime frame: Pre-dose and after the end of PK-sampling (720 minutes post-dose)
  8. Tolerability: Pain assessments per Visual Analogue Scale (VAS)Time frame: 10 min and 1 hour post-dosing
  9. Tolerability: Change in Interleukin 6 [IL-6] levelsTime frame: Blood samples will be taken immediately before dosing, 2 hours after dosing, and with the last PK sample (720 minutes after dosing)
  10. Tolerability: Change in tumor necrosis factor [TNF-α] levelsTime frame: Blood samples will be taken immediately before dosing, 2 hours after dosing, and with the last PK sample (720 minutes after dosing)
  11. Tolerability: Change in high sensitivity C-reactive protein [hsCRP] levelsTime frame: Blood samples will be taken immediately before dosing, 2 hours after dosing, and with the last PK sample (720 minutes after dosing)
  12. Pharmacokinetic: Area under the insulin concentration-time curve (AUC)Time frame: From the time of dose (time 0) until 12 hours post-dose (AUCIns,0-12h)
  13. Pharmacokinetic: Maximum insulin concentration (Cmax)Time frame: Over 12 hours post-dosing
  14. Pharmacokinetic: Time to maximum insulin concentration (Tmax)Time frame: Over 12 hours post-dosing
  15. Glucodynamic: Area under the glucose infusion rate (GIR) time curveTime frame: From the time of dose (time 0) until 12 hours post-dose (AUCGIR,0-12h)
  16. Glucodynamic: Maximum GIR (GIRmax)Time frame: Over 12 hours post-dosing
  17. Glucodynamic: Time to maximum GIR (TGIRmax)Time frame: Over 12 hours post-dosing

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • ProSciento, Inc.

    Chula Vista, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.